We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-2.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.7B
AUM Growth
-$733M
Cap. Flow
+$511M
Cap. Flow %
4.78%
Top 10 Hldgs %
33.24%
Holding
188
New
39
Increased
39
Reduced
24
Closed
30

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$452M
2
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$186M
3
CMMB
Chemomab Therapeutics
CMMB
+$128M
4
HAE icon
Haemonetics
HAE
+$105M
5
IRON icon
Disc Medicine
IRON
+$86.6M

Top Sells

Rank Stock Value
1
PRLD icon
Prelude Therapeutics
PRLD
+$369M
2
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$319M
3
PFE icon
Pfizer
PFE
+$133M
4
BIIB icon
Biogen
BIIB
+$121M
5
CNC icon
Centene
CNC
+$120M

Sector Composition

Rank Sector Weight
1 Healthcare 94.88%
2 Technology 0.12%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
76
uniQure
QURE
$2.52B
$32.6M 0.31%
969,079
– –
ALPN
77
DELISTED
Alpine Immune Sciences Inc
ALPN
$32.6M 0.3%
3,070,955
– –
SCPH
78
DELISTED
scPharmaceuticals
SCPH
$31.9M 0.3%
4,797,148
– –
SYRE icon
79
Spyre Therapeutics
SYRE
$8.68B
$31.8M 0.3%
160,621
– –
PAND
80
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$31.7M 0.3%
528,229
-952,711
-64% -$34.5M
MRSN
81
DELISTED
Mersana Therapeutics
MRSN
$30.6M 0.29%
75,700
+44,766
+145% +$21.7M
NMTR
82
DELISTED
9 Meters Biopharma
NMTR
$30.1M 0.28%
1,285,838
– –
NVAX icon
83
Novavax
NVAX
$1.21B
$28.3M 0.26%
+155,833
New +$31.1M
NXTC icon
84
NextCure
NXTC
$22.1M
$27.1M 0.25%
225,918
– –
ACHL
85
DELISTED
Achilles Therapeutics
ACHL
$26.2M 0.25%
+1,584,845
New +$26.2M
SRRA
86
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$25.5M 0.24%
1,477,320
– –
DMRA
87
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.81B
$24.9M 0.23%
163,637
– –
CRVS icon
88
Corvus Pharmaceuticals
CRVS
$1.12B
$24.8M 0.23%
8,053,298
+1,285,714
+19% +$4.64M
CALC icon
89
CalciMedica
CALC
$11.3M
$23.1M 0.22%
297,382
-22,321
-7% -$6.68M
ELVN icon
90
Enliven Therapeutics
ELVN
$3.84B
$23M 0.21%
679,976
– –
BIIB icon
91
Biogen
BIIB
$30.4B
$22.9M 0.21%
82,000
-447,400
-85% -$121M
ALXN
92
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$22.9M 0.21%
+150,000
New +$23.2M
AMGN icon
93
Amgen
AMGN
$212B
$22.8M 0.21%
91,500
– –
VRCA icon
94
Verrica Pharmaceuticals
VRCA
$92.8M
$22.4M 0.21%
147,973
– –
CTIC
95
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$21.9M 0.2%
7,520,600
-2,000,000
-21% -$6.53M
OLMA icon
96
Olema Pharmaceuticals
OLMA
$1.01B
$21.8M 0.2%
656,126
+5,134
+0.8% +$220K
LAB icon
97
Standard BioTools
LAB
$311M
$20.8M 0.19%
4,599,571
+707,225
+18% +$3.88M
FLXN
98
DELISTED
Flexion Therapeutics, Inc.
FLXN
$20.7M 0.19%
2,308,083
– –
KDNY
99
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$19.4M 0.18%
1,250,001
– –
JNCE
100
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$18.7M 0.18%
+1,823,600
New +$20M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2021 Portfolio in Review

As of Q1 2021, OrbiMed held 188 positions worth $10.7B, down 6.4% from $11.4B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed deployed $511M of net new capital in Q1 2021, opening 39 new positions and adding to 39 existing holdings. Its largest new stake was Edgewise Therapeutics: 13,944,680 shares worth $453M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Prelude Therapeutics, an estimated $369M trimmed.

  • OrbiMed's largest Q1 2021 buy was Edgewise Therapeutics: 13,944,680 shares worth $453M.
  • OrbiMed added most to Merck in Q1 2021, an estimated $83M increase.
  • OrbiMed's biggest Q1 2021 reduction was Prelude Therapeutics, cutting an estimated $369M.
  • OrbiMed fully exited Prevail Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $319M.
  • OrbiMed's ten largest holdings make up 33% of its $10.7B portfolio in Q1 2021.
  • OrbiMed opened 39 new positions and closed 30 in Q1 2021.
  • OrbiMed's portfolio value fell 6.4% quarter-over-quarter to $10.7B.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.